VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc., a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation bispecific and multifunctional biotherapeutics, initially focused on the treatment of cancer, today announced that its abstract has been accepted for Poster Presentation at the 2016 American Society of Hematology Annual Meeting and Exposition, being held from December 3-6, 2016 in San Diego, California.
Zymeworks will present at the following session:
- Session Information: 625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Poster I
- Abstract Title: ZW38, a Novel Azymetric Bispecific CD19-Directed CD3 T Cell Engager Antibody Drug Conjugate with Controlled T Cell Activation and Improved B Cell Cytotoxicity
- Date: December 3, 2016
- Time: 5:30 p.m. – 7:30 p.m. PST
- Location: San Diego Convention Center, Hall GH
About Zymeworks Inc.
Zymeworks is a clinical-stage
biopharmaceutical company dedicated to the discovery, development and
commercialization of next-generation bispecific and multifunctional
biotherapeutics, initially focused on the treatment of cancer. The
Company’s Azymetric™, AlbuCORE™, and EFECT™ platforms, its Zymelink™
conjugation platform and cytotoxins, and its proprietary ZymeCAD™
structure-guided protein engineering technology, provide the flexibility
and compatibility to precisely engineer and develop
highly-differentiated product candidates. The Company’s lead product
candidate, ZW25, is a novel bispecific antibody being evaluated in a
Phase 1 clinical trial. Zymeworks is also advancing a pipeline of
preclinical product candidates and discovery-stage programs in
immuno-oncology and other therapeutic areas. In addition to the
Company’s wholly-owned pipeline, its therapeutic platforms have been
further leveraged through multiple strategic partnerships with global
biopharmaceutical companies. More information on Zymeworks can be found
at www.zymeworks.com.
